Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 06, 2025 17:30 ET  | Source: Fulcrum Therapeutics, Inc. ― Clear…
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
Rilzabrutinib granted orphan drug designation in the US for sickle cell disease…